







Introduction The prevalence of bronchial asthma, which is a chronic inflammatory 
disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) 
play a central role in the treatment of asthma, they cannot achieve good control for all 
asthmatics and medications such as leukotriene receptor antagonists (LTRAs) with 
bronchodilatory and anti-inflammatory effects often serve as alternatives or add-on 
drugs. 
Areas covered Clinical trials as well as basic studies of montelukast and pranlukast in 
animal models are ongoing. This review report clarifies the current status of these two 
LTRAs in the treatment of asthma and their future direction.  
Expert opinion Leukotriene receptor antagonists could replace ICS as first-line 
medications for asthmatics who are refractory to ICS or cannot use inhalant devices. 
Furthermore, LTRAs are recommended for asthmatics under specific circumstances that 
are closely associated with cysteinyl leukotrienes (cysLTs). Considering the low 
incidence of both severe adverse effects and the induction of tachyphylaxis, oral LTRAs 
should be more carefully considered for treating asthma in the clinical environment. 
Several issues such as predicted responses, effects of peripheral airway and airway 
remodeling and alternative administration routes remain to be clarified before LTRAs 
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could serve a more effective role in the treatment of asthma. 
 


















AHR, airway hyperresponsiveness  
AIA, aspirin intolerant asthma  
AR, allergic rhinitis   
ASM, airway smooth muscle cells 
COX, cyclooxygenase 
CSS, Churg Strauss syndrome  
CVA, cough variant asthma  
CysLT, cysteinyl leukotriene  
DC, dendritic cell(s)  
EIB, exercise-induced bronchoconstriction  
FEV1.0, forced expiratory volume in one second  
FLAP, 5-lipoxigenase (5-LO)-associated protein 
ICS, inhaled corticosteroid;  
LABA, long acting β2 agonist   
LTRA, leukotriene receptor antagonist  
NSAID non steroidal anti inflammatory drug  
PMA, premenstrual asthma  
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RCT, randomized control trial  
SABA, short acting β2 agonist  
SRS-A, slow reacting substance of anaphylaxis  
URI, upper respiratory tract infection  
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Introduction 
1. Pathophysiology and epidemiology of asthma 
Bronchial asthma is a respiratory disease that affects an estimated 315 million 
individuals of all ages worldwide [1]. Asthma is clinically characterized by the acute 
onset of dyspnea with expiratory stridor and reversible airway obstruction. The primary 
pathophysiology of asthma is airway hyperresponsiveness (AHR) to various stimuli 
associated with allergic airway inflammation. Various types of cells and mediators are 
involved in the development and exacerbation of allergic airway inflammation [2]. 
Asthma is also characterized by structural change of the airway wall, especially 
following long periods. The term “airway remodeling” includes goblet cell metaplasia, 
thickening of the reticular layer beneath the true basement membrane, smooth muscle, 
fibroblast and myofibroblast hyperplasia [3-5]. Such airway remodeling is thought to be 
associated with AHR and the irreversible airway obstruction found in patients with 
chronic asthma. Asthma is primarily a chronic respiratory disorder, while acute 
exacerbation occasionally occurs following upper respiratory tract infection and could 
be fatal. Recent advances in the treatment of asthma have reduced the incidence of 
fatalities among asthmatics. Nonetheless, the prevalence of asthma in both children and 
adults is increasing worldwide. The annual direct medical expenditure for asthma 
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treatment in the USA in 2007 was USD 37.2 billion [6]. In Europe, the estimated annual 
direct cost of asthma is EUR 7.9 billion [7]. Furthermore, the total incremental cost 





In 1960, Brocklehurst discovered a substance in guinea pigs that could constrict 
smooth muscle and was distinct from histamine. He named his discovery slow reacting 
substance of anaphylaxis (SRS-A) due to its delayed onset and protracted activity [9]. 
Thereafter, Samuelsson and colleagues identified SRS-A as cysteine-containing 
conjugated triene derivatives of the fatty acid arachidonic acid and collectively called 
them leukotrienes (LT) [10]. Samuelsson received the Nobel Prize in Physiology or 
Medicine for this discovery in 1982. 
2.2 Biosynthesis and receptors of LTs  
Inflammatory cells including eosinophils, mast cells and macrophages in the airway 
predominantly produce leukotrienes (Figure 1). Many stimuli including allergens and 
viral infections initiate LT production from arachidonic acid in the cellular membrane 
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by activating phospholipase A2 (PLA2). First, the enzyme 5-lipoxygenase (5-LO) and 
its helper protein, 5-LO-activating protein (FLAP) produces LTA4, which is converted 
by LTC4 synthase to LTC4 or by LTA4 hydrase to LTB4. Neutrophils in asthmatic 
airways produce LTB4, which is less well characterized. Leukotriene C4 is then 
converted to LTD4 and LTE4. Slow reacting substance of anaphylaxis comprises LTC4, 
D4 and E4 that are now termed cysteinyl LTs (cysLTs) and they are predominantly 
produced from eosinophils and mast cells in asthmatic airways. All cysLTs act thorough 
G protein-coupled receptors on the cell surface. The best characterized cysLTs receptors 
are cysLT1R and cysLT2R. The binding affinity of CysLT1R is LTD4 > LTC4 or LTE4, 
whereas that of cysLT2R is LTC4 = LTD4 > LTE4. The ligation of cysLTs and cysLTR1 
results in bronchoconstriction, mucous secretion and edema. The ligation of cysLTs and 
cysLTR2 results in airway inflammation and fibrosis [11], although their primary roles 
in the pathogenesis of asthma remain uncertain. Leukotriene E4 binds poorly to both 
cysLT1R and cysLT2R, suggesting the involvement of LTE4 receptors [12]. The 
receptors for LTB4 include BLT1 and BLT2. 
2.3 Action of cysLTs in asthma 
Several studies have determined higher concentrations of cysLTs in the airways and 
urine of asthmatics compared with non-asthmatic individuals [13]. The production of 
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cysLTs is increased in asthmatics, particularly during the early phase of 
bronchoconstriction that follows allergen challenge [14]. Cysteinyl LTs have far more 
powerful bronchoconstrictive effects than either methacholine or histamine, they induce 
AHR, vascular permeability and mucous production and exert proinflammatory effects 
including chemotactic activity for eosinophils and cytokine production from 
lymphocytes [15, 16]. All of these actions are closely associated with the pathogenesis 
of asthma. Cysteinyl LTs also have mitogenic effects on airway smooth muscle cells 
(ASM) that might be closely associated with airway remodeling [17]. Taken together, 
cysLTs seem to be critically involved in the symptoms, acute exacerbation and 
persistence of asthma. 
 
3. Leukotriene receptor antagonists 
3.1 Drug development 
Since their discovery, cysLTs have been regarded as candidate drugs for treating 
asthma and pranlukast became commercially available in Japan during 1995 as a new 
class of antiasthma drugs, followed by montelukast in Mexico during 1997. Two classes 
of anti-LT drugs, 5-LO inhibitor (zileuton) and LT receptor antagonists (LTRA; 
pranlukast, montelukast, zafirlukast) are currently available. The present review focuses 
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on pranlukast and montelukast (Figure 2). Both are specific cysLTR1 antagonists that 
do not antagonize cysLTR2. Montelukast is administered once daily, whereas pranlukast 
is administered twice daily. Their clinical benefits seem comparable despite some 
differences in their pharmacokinetics.  
3.2 Pharmacology 
As predicted from the biological effects of cysLTs, LTRAs reduce 
bronchoconstriction in response to various stimuli. Leukotriene receptor agonists 
significantly reduce anaphylactic bronchoconstriction in passively sensitized human 
lung parenchyma in vitro compared with other anti-allergic drugs [18]. Leukotriene 
receptor agonists also have anti-inflammatory effects in a murine model of allergic 
asthma as they reduce airway eosinophilia and cytokine production from T lymphocytes 
[16]. Heterogeneous effects are characteristic of LTRAs. Although the reason for this 
heterogeneity remains unclear, some genetic and acquired factors have been suggested. 
This heterogeneity also results in some specific indications for which LTRAs are 
particularly effective as will be described in detail later. At present, however, no 
laboratory measures can predict responses to LTRAs including cysLT production in 
urine or sputum. Although pranlukast might have anti-inflammatory effects via a 




4. Clinical use of LTRA for asthma 
4.1 Asthma treatment guidelines 
The current asthma treatment guidelines consider that asthma is a chronic inflammatory 
disorder of the airways and that inhaled corticosteroid (ICS) is a first line therapy. 
Leukotriene receptor antagonists are classified as acceptable alternative first line 
therapies for mild asthma and also considered an alternative to long acting β2 agonists 
(LABA) as ICS add-on therapy in moderately persistent asthma. 
4.2 First-line therapy 
Inhaled corticosteroids are the standard first-line therapy for any severity of asthma. 
Although the anti-inflammatory properties of LTRAs are less powerful than those of 
ICS, LTRA monotherapy might be effective for mild asthma. Randomized control trials 
(RCT) of montelukast have shown significant improvements in lung function, 
symptoms, QOL, rescue with short acting β2 agonists (SABA) and exacerbation [21, 
22]. A meta-analysis has also shown that LTRA monotherapy is significantly less 
clinically effective against mild to moderate asthma than low-dose ICS [23]. 
Considering compliance, monotherapy with LTRA could be substituted for that with 
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ICS in mild asthmatics for whom inhalers are not an option. In fact, whereas therapeutic 
compliance with ICS is low in the clinical setting, the effects on pulmonary function 
and QOL are comparable between monotherapy with montelukast and ICS [24].  
4.3 Add-on therapy 
The most common role of LTRA is that of add-on therapy for uncontrolled asthma 
on patients treated with ICS. The rationale for this is that steroids cannot inhibit cysLT 
production [25]. Similarly to other chronic diseases such as hypertension and infection, 
combined medications are potentially more effective than simply increasing the dose of 
a single drug. Adding pranlukast or montelukast to ICS significantly improves 
symptoms and pulmonary functions to a degree comparable to that of doubling the ICS 
dose for patients with uncontrolled asthma [26, 27]. As add-on medication to ICS, the 
asthma treatment guidelines also recommend slow-release theophylline and LABA as 
well as LTRA. The bronchodilatory effects of add-on pranlukast to medium doses of 
ICS are comparable to those of theophylline [28]. Combinations of ICS and LABA 
comprise the most prevalent option for treating moderate, to severe asthma. Many RCT 
have found that adding LABA to ICS results in significantly better outcomes that those 
generated by LTRA [29-32]. However, these studies might have some critical 
limitations. Firstly, participants in RCT generally have bronchial obstruction that is 
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reversible by SABA, which potentially proves the effectiveness of LABA at entry. 
Secondly, individuals with obesity, a smoking history and recent viral respiratory 
infection who might be good responders to LTRA are generally excluded from RCT. In 
fact, a clinic-based, real-world study from which participants could not be strictly 
excluded found comparable add-on effects between LTRA and LABA [24]. Thirdly, 
many RCT have compared bronchodilatory effects such as peak expiratory flow and 
forced expiratory flow volume in one second (FEV1.0) between LTRA and LABA and 
have found that LABA are more effective than LTRA, which are primarily considered as 
anti-inflammatory controllers despite having bronchodilatory effects that are inferior to 
those of LABA. One study found that LABA improved bronchodilatory effects more 
effectively, whereas montelukast had better anti-inflammatory effects including 
peripheral blood eosinophil counts [33]. Although the clinical relevance of the 
anti-inflammatory properties of LTRA remain to be determined, adding LTRA to ICS 
over the long-term could probably prevent the progression of airway remodeling, since 
LTRA have anti-remodeling effects in humans and other animals with asthma as 
described below. Montelukast has also been added to ICS and LABA. This triple 
combination significantly improved the QOL of patients compared with a combined ICS 
and LABA [34]. Even when pulmonary function is normal in asthmatics on high-dose 
PAGE 14 
ICS and LABA, cysLTs can be detected in induced sputum. Adding on pranlukast for 
these patients significantly attenuated cysLTs and pro-inflammatory cytokines in 
induced sputum [35]. Taken together, the current asthma treatment guidelines might 
under-represent the usefulness of LTRA, especially in the real-world setting and under 
the following specific situations. 
4.4 Established situations for which LTRAs are preferential 
Leukotriene receptor agonists are currently prescribed for all asthmatics. However, 
they might be particularly effective for treating subsets of asthmatics. 
Exercise induced bronchoconstriction (EIB) 
Over half of all asthmatics develop exercise-induced bronchoconstriction. Although 
the underlying mechanisms of EIB remain unknown, several inflammatory mediators 
including cysLTs might be involved [36]. The administration of SABA, disodium 
cromoglycate and LTRA before exercise can prevent EIB.  Montelukast prevents 
pulmonary function from maximally decreasing after exercise in children with EIB 
significantly more effectively than ICS [37]. Repeated administration with β2-agonists 
results in tachyphylaxis, whereas that of LTRA does not. Montelukast persistently 
prevents EIB even after four and eight weeks of administration, whereas the preventive 
effects of salmeterol, a LABA, were attenuated [38]. 
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Aspirin intolerant asthma (AIA) 
About 10% of adult asthmatics develop acute severe bronchoconstriction after 
being medicated with non-steroidal anti-inflammatory drugs (NSAIDs) including 
aspirin. The prevalence of AIA is higher among 40 – 50-year-old women than among 
men. Common complications include nasal polyps and anosmia. The shunt theory states 
that the 5-LO pathway dominates the cyclooxygenase (COX) pathway in patients with 
AIA. Inhibition of the COX pathway by NSAIDs activates arachidonic acids through 
the 5-LO pathway to produce excessive amounts of cysLTs in AIA, which results in 
bronchoconstriction. Significantly more CysLTs are produced in patients with 
aspirin-intolerant, than tolerant asthma [39]. Thus, LTRA should be useful for treating 
AIA. In fact, adding montelukast to ICS to treat patients with symptomatic AIA 
significantly improves their QOL [40]. Pranlukast partially, but significantly reduces the 
fall in oral aspirin-induced FEV1.0 in patients with AIA [41, 42]. 
Perimenstrual asthma (PMA) 
Symptoms worsen in 30% - 40 % of pre-menopausal women with asthma during 
the premenstrual or menstrual period. Although the exact mechanism of PMA remains 
unknown, cysLTs as well as sex hormones seem to be involved [43]. Perimenstrual 
asthma includes severity that warrants treatment with systemic corticosteroids [44, 45]. 
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Both pranlukast and montelukast significantly improve asthma symptoms and 
pulmonary functions, indicating that LTRAs could be effective against PMA [46, 47]. 
Cough variant asthma (CVA) 
Chronic persistent cough is one of the most prevalent symptoms worldwide. 
Although chronic cough has may causes, CVA is the most frequent source when both 
chest X ray and auscultation findings are normal. Cough variant asthma is defined as 
asthma with cough as the predominant or sole symptom with minimal 
bronchoconstriction. Airway hyper-responsiveness with eosinophilic airway 
inflammation is also found in CVA. Bronchodilators can relieve cough associated with 
CVA and ICS is the mostly frequently recommended medication. However, patients 
with CVA in the real world cannot inhale deeply and severe coughing interrupts 
breathing; thus oral LTRAs might be reasonable add-ons or alternatives for such 
patients. Montelukast has significantly reduced cough symptoms and suppressed airway 
inflammation [48]. One study compared the antitussive effects of pranlukast and LABA 
in patients with CVA and found that pranlukast can significantly reduce cough scores 
[49].  
Asthma with concomitant allergic rhinitis (AR) 
Allergic rhinitis is a comorbidity associated with the severity of asthma that affects 
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30% - 60% of asthmatics [50]. Treating AR improves asthma symptoms and intranasal 
steroids reduce asthma-related symptoms as well as AHR [51]. From this perspective, 
LTRAs are ideal because they can treat both AR and asthma. For uncontrolled moderate 
persistent asthma, the effects of adding montelukast to moderate-dose ICS on 
pulmonary function are considered comparable to double doses of ICS. While, in the 
subgroup of asthmatic patients with AR, a combined treatment approach that included 
montelukast and ICS provided significantly greater efficacy in reducing airflow 
obstruction compared with doubling the dose of ICS [52]. Accordingly, the current 
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend LTRAs for 
treating asthma in patients with AR who are unable to use ICS [53]. 
Infection-induced asthma 
Upper respiratory infection (URI) caused by respiratory viruses exacerbates about 
50% of adult asthmatics and 80% of children with asthma and it is treated similarly to 
asthma due to other causes. Systemic CSs and SABA are central medications for 
URI-induced acute asthma. Treatment of URI-induced acute asthma remains 
complicated by several issues. Firstly, systemic CSs are extremely effective against 
acute asthma, but they potentially inhibit anti-viral immunity [54]. Secondly, viral 
infection attenuates the anti-inflammatory effects of CSs [55]. Thirdly, viral infection 
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also attenuates the effects of β2 agonists [56]. These problems can be overcome by 
adding other drugs to CSs and SABA. From this perspective, LTRAs are attractive 
because cysLTs increase in the airway after URI [57-59], cysLTR1 also increases in the 
airway of acute exacerbated asthma [60], LTRAs have acute bronchodilator effects and 
they selectively inhibit pro-inflammatory cytokines in contrast to CS, which 
non-selectively inhibits cellular immunity [61]. In fact, adding pranlukast to systemic 
CSs significantly shortened the duration of symptoms and reduced the total dose of 
systemic CS compared with systemic CS therapy alone in patients with questionnaire 
confirmed URI-induced acute asthma [62]. Daily montelukast also prevents the 
development of URI-induced acute asthma exacerbation in 30% of children with asthma 
[63].  
Obesity 
Obesity has recently emerged as a potential critical risk factor for developing and 
exacerbating asthma and it causes CS resistance in patients with asthma. The 
mechanism of obesity-exacerbated asthma includes physical obstruction by fat tissue 
and systemic inflammation associated with fat tissue [64]. Fat tissue produces many 
pro-inflammatory mediators [65], among which are cysLTs. Body mass index (BMI) is 
associated with LTE4 production in adult asthmatics [66]. The therapeutic responses of 
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asthmatics to ICS decrease with increasing BMI, whereas those to montelukast remain 
stable [67]. 
Smoking 
Smoking is also regarded as a critical risk factor for worsening asthma. Smoking 
inhibits almost all steroid-related anti-inflammatory effects and thus causes CS 
resistance in asthmatics who smoke [68]. One mechanism of CS resistance is 
smoking-induced csyLT production. Habitual cigarette smoking causes a 
dose-dependent increase in cysLT production [69]. One study found that the response to 
ICS is attenuated in smokers with mild asthma, whereas the response is greater in 
asthmatic smokers treated with montelukast, suggesting that cysLTs could be important 
for treating such individuals [70]. Patients with a smoking history of less than 11 pack 
years tend to show more benefit with ICS, whereas those with a smoking history of 
greater than 11 pack years tended to show more benefit with montelukast [71]. 
Elderly persons with asthma 
Asthma is common disorder in not only young generation but also in elderly 
patients. Elderly asthmatics are frequently misdiagnosed such as chronic heart failure or 
chronic obstructive pulmonary diseases. Even when asthma is adequately diagnosed, 
anti-asthma therapies for the elderly are often difficult to implement due to poor 
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inhalation technique, poor compliance with inhaled medicines, decreased cognitive 
function and comorbidities. The recent increase in the mortality rate due to asthma 
among elderly patients might thus be associated with insufficient diagnosis and 
treatment [72]. Leukotriene receptor agonists are valuable medications for elderly 
persons since they are orally administered and have less severe adverse effects. 
Montelukast as add-on therapy to ICS for severe asthmatics aged > 60 years reduces 
asthma exacerbation events and increases the number of symptom-free days [73]. 
4.5 Uncertain areas regarding LTRA preference 
Sex 
Sex differences in cysLT production have recently been identified [74]. 
Significantly more cysLTs are produced by stimulated white blood cells from women 
than from men. The distribution of enzymes in white blood cells that synthesize LTs 
differs between men and women. Male sex hormones inhibit cysLT production by white 
blood cells from women. The prevalence of AIA, which is closely related to cysLTs, is 
higher and asthma is more frequently severe in women, which might be partially 
associated with sex differences in cysLT production. Although a clinical study has found 
increased cysLT-related albuterol usage and a greater tendency towards montelukast 
responsiveness in girls than in boys exposed to tobacco smoke [75], whether the clinical 
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effects of LTRAs are in fact associated with sex with remains undetermined. 
Peripheral airways 
Recent findings support the concept that not only central, but peripheral airways are 
involved in allergic airway inflammation and obstruction, especially in severe asthma 
[76, 77]. Furthermore, the density of inflammatory cells is greater in the outer, than in 
the inner airway walls of asthmatic peripheral airways [78]. Additionally, more 
cysLTR1 is expressed in fibroblasts from the peripheral, than the central airway [79]. 
Since inhaled medicines cannot easily penetrate the outer walls of peripheral airways, 
oral LTRAs that can be delivered to peripheral airways via the bloodstream might be a 
useful add-on therapy to inhibit peripheral airway inflammation. Montelukast inhibits 
allergic inflammation in the small airways of guinea pigs in vitro [80] and both 
pranlukast and montelukast attenuate peripheral airway inflammation and obstruction in 
humans with asthma [81, 82]. 
Airway remodeling 
Airway remodeling is currently thought to be associated with fixed airway 
obstruction and AHR. Considerable evidence suggests that cysLTs are involved in the 
development of airway remodeling. The ideal therapy for asthma should prevent both 
airway inflammation and remodeling. However, whether or not regular therapy with 
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ICS affects airway remodeling remains controversial [83-87]. Montelukast has reversed 
established airway smooth muscle cell layer thickening and sub-epithelial fibrosis in a 
murine model of allergic asthma [88] and Kelly et al. showed using endobronchial 
biopsy specimens that eight weeks of montelukast treatment attenuated the increase in 
myofibroblasts subsequent to allergen challenge in patients with mild asthma [89]. Thus, 
LTRAs have the potential to attenuate airway remodeling in asthma. However, data 
supporting this notion remain scant. 
Prevention of asthma 
Cysteinyl LTs are involved in not only the worsening and maintenance of 
established asthma but also in its development. Primary antigen-presenting dendritic 
cells (DC) in the airway express cysLT1R and produce cysLTs upon antigen stimulation 
[90, 91]. Intranasal inoculation with allergen-sensitized DCs into the airway of naïve 
mice results in allergic airway inflammation and incubating allergen-sensitized DCs 
with LTRAs inhibited the subsequent development of allergic airway inflammation in a 
murine model [92]. Thus, LTRAs might prevent the development of subsequent asthma 





The safety as well as the efficacy issue of control medications should be considered. 
Both pranlukast and montelukast are generally well tolerated and the incidence of 
severe adverse effects low [93]. A long-term follow-up study has confirmed the safety 
of LTRAs as well as the absence of the tachyphylaxis induced by β2-agonists [94]. 
Despite a small sample size, a recent study of perinatal outcomes in asthmatics 
administered with LTRAs or SABA and in those without asthma found that the use of 
LTRAs during pregnancy does not result in adverse perinatal outcomes including 
specific structural abnormalities [95]. Montelukast is presently classified as a grade B 
drug for pregnant women. The present safety concerns regarding LTRAs comprise the 
induction of Churg Strauss Syndrome (CSS) and neuropsychiatric disorders [93]. 
However, data supporting a relationship between LTRA and these adverse events remain 
conclusive. Adult patients with asthma severe enough to require high-dose ICS and/or 
systemic CS generally develop CSS. Since the clinical symptoms of CSS generally 
develop during CS reduction by add-on LTRAs, LTRAs might unmask, rather than 
induce CSS. Physicians should carefully reduce ICS by adding LTRAs for patients with 
severe asthma who require high-dose ICS and/or oral steroids. Although the 
development of neuropsychiatric disorders might be due to allergies or severe asthma 
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itself, a history of behavioral disturbances should be carefully assessed before 
administering LTRAs to patients.  
 
5. Conclusion 
Since the initiation of their clinical use, several studies have helped to clarify the 
status of LTRAs including pranlukast and montelukast in the treatment of asthma. 
Asthma treatment guidelines primarily consider LTRAs as alternative or add-on 
medications to ICS because their anti-inflammatory effects are less powerful than those 
of ICS. However, adherence, especially with inhaled CS, is relatively poor. Furthermore, 
elderly patients often have difficulties with handling inhaled devices due to decreased 
cognitive function and comorbidities. Oral problems associated with ICS can also 
prevent compliance with ICS among the elderly, who have reduced salivary production. 
Thus, LTRAs could be substituted ICS as a first-line medication for asthmatics who are 
poorly compliant with ICS or cannot use inhaled devices. In fact, a recent real-world 
study has confirmed that the effects of LTRAs as a first line therapy with ICS and 
add-on therapy are comparable to those of LABA. Similarly, LTRAs are especially 
recommended for asthmatics under specific situations that are closely associated with 
cysLTs such as EIB, AIA, PMA, CVA, asthma with concomitant AR, infection-induced 
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asthma, obesity and smoking. In addition, oral LTRAs should be considered more often 
for treating asthma in the clinical setting because of the low incidence of both severe 
adverse effects and the induction of tachyphylaxis. 
 
6. Expert opinion 
A critical defect in the clinical use of LTRAs also involves their variable effects on 
asthma. The notion that asthmatics who produce more cysLTs in urine or sputum are 
higher responders to LTRAs therapy is simply untrue and predictors of better responders 
to LTRAs before initiation are unavailable. Identifying genetic factors or surrogate 
markers that could predict responses to LTRAs will be important. 
The findings of basic and/or clinical, but not of practical research, indicate that 
LTRAs significantly affect peripheral airway and airway remodeling. However, 
peripheral airway and airway remodeling require specific modalities such as 
high-resolution computed tomography, fractional exhaled nitric oxide detectors, impulse 
oscillometry and endobronchial biopsies. Longer term and larger scale prospective 
studies as well as the development of non-invasive and clinically repeatable measures 
will definitely be important to conclude whether or not LTRAs are effective against 
peripheral airway and airway remodeling in asthma. 
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Chemoprevention for allergic diseases does not exist. Cysteinyl leukotrienes are 
critically involved in innate immunity and LTRAs act upon DCs to prevent the 
induction of allergic airway inflammation in mice. Future studies should determine 
whether LTRAs can prevent the subsequent development of asthma among patients with 
AR who are susceptible to the development of asthma. 
Since LTRAs have bronchodilatory as well as anti-inflammatory effects, intravenous 
montelukast was developed as a medication to relieve acute asthma [96] and inhalant 
montelukast was developed to directly deliver medications to the airway [97]. Although 
these forms of montelukast exert significant anti-asthmatic effects, they have not yet 
been marketed. 
Current LTRAs antagonize cysLT1R but not cysLT2R and since cysLT2R might be 
involved in the pathogenesis of asthma, the development and clinical application of dual 
antagonists might be a promising asthma treatment [98]. Besides cysLTs, antagonism of 
the LTB4 pathway is also of interest. An inhibitor of LTA4 hydrolase that inhibits LTB4 
production significantly attenuated allergic airway inflammation in a murine model of 
allergic asthma [99]. 
Besides asthma and AR, cysLTs are also associated with other human diseases [100]. 
The expression of cysLTR1 increases in the airway of patients with acute exacerbated 
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COPD and cysLT levels are increased in bronchoalveolar fluids from patients with 
idiopathic pulmonary fibrosis. Cysteinyl leukotrienes are also potentially associated 
with cardiovascular diseases and malignancy. The clinical benefits of LTRAs for these 
















Article highlights box 
 Pranlukast and montelukast are leukotriene receptor antagonists, which are specific 
cysLT1R antagonists. 
 Leukotriene receptor antagonists are classified as acceptable alternative first line 
therapies for mild asthma and also considered an alternative to LABA as ICS 
add-on therapy in moderately persistent asthma. 
 Leukotriene receptor antagonists might be particularly effective for treating subsets 
of asthmatics including EIB, AIA, PMA, CVA, asthma with concomitant AR, 
infection-induced asthma, obesity, smoking and elderly subjects. 
 Both pranlukast and montelukast are generally well tolerated and the incidence of 
severe adverse effects low. 
 Several issues such as predicted responses, effects of peripheral airway and airway 
remodeling and alternative administration routes remain to be clarified before 







Figure 1. Biosynthesis and receptors of leukotrienes. 
BLT, LTB4 receptor; CysLT, cysteinyl LT; CysLTR, cysLT receptor; FLAP, 5-LO 
associated protein; LT, leukotriene; LTA4H, LTA4 hydrolase; LTC4S, LTC4 synthase;  
PLA2,  phospholipase A2;  5-LO: 5-lipoxygenase.  
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